Here are the Form 4 insider transactions from Insight Molecular Diagnostics Inc. (IMDX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IMDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMDX filings page.
Insight Molecular Diagnostics Inc. director Lou Silverman reported a routine tax-related share disposition. On July 1, 2026, 7,700 shares of common stock valued at $5.69 per share were withheld by the company to cover tax obligations from the vesting of 35,000 restricted stock units granted on July 1, 2025. The footnote clarifies that Silverman did not sell any shares in the market, and he now directly holds 55,807 shares after this withholding.
Insight Molecular Diagnostics Inc. director Andrew J. Last reported a routine tax-withholding transaction related to equity compensation. On the vesting of 35,000 restricted stock units granted on July 1, 2025, the company withheld 7,700 shares of common stock at a value of $5.69 per share to cover tax obligations. This was not an open-market sale, and the reporting person did not sell any shares. After this withholding, Last directly holds 58,752 shares of common stock.
Insight Molecular Diagnostics Inc. director Arno Andrew reported the vesting of 55,000 restricted stock units, with part of the award used to pay taxes. The company withheld 12,100 shares of Common Stock at a value of $5.69 per share to satisfy tax withholding obligations, and the filing states that no shares were sold on the market. After this tax-withholding disposition, Andrew directly holds 156,785 shares of Common Stock and also has indirect holdings through entities JBA Investments LLC and MJA Investments LLC, where he serves as manager with voting and dispositive power.
SILVERMAN LOU reported acquisition or exercise transactions in this Form 4 filing.
Insight Molecular Diagnostics Inc. director Lou Silverman reported an equity award of 26,943 shares of Common Stock on 2026-06-11. These shares are structured as Restricted Stock Units that vest on the date of the next annual meeting of shareholders, contingent on his continued service through that date.
Following this grant, Silverman directly holds a total of 63,507 shares of Common Stock. The award carries a stated price of $0.00 per share, indicating it is compensation rather than an open-market purchase.
Insight Molecular Diagnostics Inc. director Andrew J. Last reported an equity award on Common Stock. He received 26,943 Restricted Stock Units at a price of $0.00 per share, increasing his direct holdings to 66,452 shares.
The Restricted Stock Units will vest on the date of the next annual meeting of shareholders, provided he continues serving the company from the grant date through that vesting date. This filing reflects routine, compensation-related share acquisition rather than an open-market purchase or sale.
Arno Andrew reported acquisition or exercise transactions in this Form 4 filing.
Insight Molecular Diagnostics director Arno Andrew received an equity grant. He was awarded 32,331 shares of Common Stock at a price of $0.00 per share as a grant or award. These Restricted Stock Units vest at the next annual meeting of shareholders, subject to his continued service. Following the grant, he directly holds 168,885 shares and also has 7,804 shares held indirectly through investment LLCs where he has voting and disposition power.
Insight Molecular Diagnostics Inc. insider Broadwood Partners, L.P., together with related entities, reported net open-market purchases of 570,184 shares of IMDX common stock. The buys occurred between April 23 and April 27 in multiple tranches at weighted average prices around $3.50–$3.64 per share.
After these transactions, entities associated with Neal C. Bradsher report holding 12,684,884 shares of common stock, plus warrants currently exercisable for a total of 300,186 additional shares at an exercise price of $30.60 per share that expire on April 19, 2027.
Insight Molecular Diagnostics Inc. shareholder entities associated with Broadwood Partners, L.P. and Neal C. Bradsher reported open-market purchases of 182,861 shares of common stock. The shares were bought between April 16 and April 20 at weighted average prices of $3.4457, $3.5711, and $3.8822 per share, across specified price ranges disclosed in the footnotes.
Following these transactions, Broadwood Partners is shown with 12,114,700 indirectly owned Insight Molecular common shares, while Neal C. Bradsher directly owns a small additional common stock position. The filing also lists currently exercisable warrants, held both directly and indirectly, each for 150,093 underlying shares at an exercise price of $30.60 per share expiring on April 19, 2027.
Insight Molecular Diagnostics Inc. Chief Financial Officer James Andrea reported routine equity compensation activity. On March 26, 2026, 28,302 Restricted Stock Units (RSUs) vested into an equal number of common shares under the company’s 2018 Equity Incentive Plan.
The company withheld 11,298 common shares at $4.11 per share to cover required tax obligations, and the filing states that the reporting person did not sell any shares. After these transactions, he directly holds 206,060 common shares and 84,905 RSUs. The RSU award vests over four years, with 25% vesting on March 26, 2026 and the remaining 75% vesting in equal annual installments, subject to continued service.
Insight Molecular Diagnostics Inc. reported that VP, Controller and Treasurer Liu James Yang had restricted stock units vest into 6,289 shares of common stock on March 26, 2026 under the 2018 Equity Incentive Plan. The company withheld 2,578 shares at $4.11 per share to cover tax obligations, and no shares were sold. After these transactions, Yang directly holds 3,711 shares of common stock and 12,578 restricted stock units, with the remaining units scheduled to vest over the next two years, subject to continued service.
Insight Molecular Diagnostics CEO Josh Riggs reported a compensation-related stock transaction involving restricted stock units (RSUs). On March 26, 2026, 47,170 RSUs vested and were converted into the same number of common shares at an exercise price of $0.00 per share under the company’s 2018 Equity Incentive Plan.
To cover required tax withholding on this vesting, 12,310 common shares were withheld by the company at $4.11 per share. The filing states that Riggs did not sell any shares; the disposition was solely for tax obligations. Following these transactions, he directly held 38,365 common shares, and the remaining 75% of the original RSU award is scheduled to vest in equal installments over the next three years, subject to continuous service.
Insight Molecular Diagnostics Inc. reported that Broadwood Partners, L.P., a 10% owner, bought additional shares of its common stock. On February 10, 2026, Broadwood Partners agreed to acquire 521,739 common shares from the company in a registered direct offering for $2,999,999, or $5.75 per share, bringing its reported beneficial ownership to 11,931,839 shares.
The filing notes that these shares are directly owned by Broadwood Partners and may be deemed beneficially owned by Broadwood Capital, Inc. and Neal C. Bradsher, who each disclaim beneficial ownership beyond their economic interest. The group also reports warrants currently exercisable for 150,093 common shares.
Insight Molecular Diagnostics (IMDX) filed a Form 4/A reporting that its Chief Financial Officer, Andrea James, had 50,000 shares of common stock issued at $0 upon vesting of performance-based RSUs on 10/31/2025. To cover taxes, 12,175 shares were withheld at $6.01; no shares were sold. Following these transactions, she directly beneficially owned 189,056 shares.
The RSUs vested after the company’s public float reached at least $75 million, satisfying a “Baby Shelf” condition that ended Form S-3 “baby shelf” limitations. This amendment corrects the original report to include the tax withholding.